Cerenome Posts First Diagnostic Revenue but Cash Falls to $4.9M
CNSY has more than doubled off its 52-week low of $0.429 on elevated volume (10× avg).
Summary
Cerenome reported Q3 2026 results with its first $0.7 million of net diagnostic revenue, but cash fell to $4.9 million from $8.6 million and the net loss widened to $8.7 million.
Key Events · Earnings and Guidance · CNSY
-
First CNSide Diagnostic Revenue Booked
Net diagnostic revenue of $0.7 million in Q3 2026 on approximately $1.55 million in gross billings at list prices, after estimated payer adjustments and price concessions.
-
Cash Falls to $4.9 Million
Cash, cash equivalents and investments dropped from $8.6 million at June 30 to $4.9 million at September 30, 2026, while the quarterly net loss widened to $8.7 million, or $1.14 per share, from $4.4 million a year earlier.
-
Funded Via Royalty Facility and ATM
The company closed a senior secured facility of up to $20 million with royalty-based repayments in September and raised $3.8M under its Equity Distribution Agreement after quarter end.
-
Payer Footprint Reaches ~190M Lives
In-network agreements with Florida Blue and Aetna (effective November 1, covering both tumor cell enumeration and molecular profiling) bring contracted coverage to roughly 190 million lives, about 80% of U.S. private payers.
Analysis · CNSY · Life Sciences
The proof point the diagnostics story needed arrived: Cerenome booked its first real product revenue, $0.7 million net on roughly $1.55 million in gross CNSide billings. Against that, the cash pile dropped from $8.6 million to $4.9 million in a single quarter while the net loss widened to $8.7 million, so the company is burning faster than it is earning and will need more capital. Management is funding the rollout piecemeal rather than from operations, having already drawn on the $20 million 3i royalty facility and raised $3.8 million under its equity distribution agreement after quarter end. What makes the revenue line repeatable is the payer build-out to roughly 190 million covered lives and the Aetna national agreement; Medicare reimbursement is targeted for the first half of 2027.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNSY was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.43 to $18.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.